» Articles » PMID: 33917315

The Consumption of Cholesterol-Enriched Diets Conditions the Development of a Subtype of HCC with High Aggressiveness and Poor Prognosis

Abstract

Non-alcoholic fatty liver disease (NAFLD) and progression to non-alcoholic steatohepatitis (NASH) result as a consequence of diverse conditions, mainly unbalanced diets. Particularly, high-fat and cholesterol content, as well as carbohydrates, such as those commonly ingested in Western countries, frequently drive adverse metabolic alterations in the liver and promote NAFLD development. Lipid liver overload is also one of the main risk factors for initiation and progression of hepatocellular carcinoma (HCC), but detailed knowledge on the relevance of high nutritional cholesterol remains elusive. We were aimed to characterize HCC development in mice fed with a Western diet (high in lipids and cholesterol) and to identify molecular alterations that define a subtype of liver cancer induced by lipid overload. Mice under western or high cholesterol diets more frequently developed tumors with a more aggressive phenotype than animals fed with a chow diet. Associated changes involved macrophage infiltration, angiogenesis, and stemness features. RNA-seq revealed a specific gene expression signature ( and ) resembling the adverse phenotypic features and poor clinical outcomes seen in patients with HCC. In conclusion; consumption of lipid enriched diets; particularly cholesterol; could accelerate HCC development with an aggressive phenotype and poor prognosis.

Citing Articles

Multidimensional landscape of non-alcoholic fatty liver disease-related disease spectrum uncovered by big omics data: Profiling evidence and new perspectives.

Zhu Z, Chen Y, Qin X, Liu S, Wang J, Ren H Smart Med. 2024; 2(2):e20220029.

PMID: 39188279 PMC: 11236021. DOI: 10.1002/SMMD.20220029.


Helicobacter pylori infection exacerbates metabolic dysfunction-associated steatotic liver disease through lipid metabolic pathways: a transcriptomic study.

Chen X, Peng R, Peng D, Liu D, Li R J Transl Med. 2024; 22(1):701.

PMID: 39075482 PMC: 11288106. DOI: 10.1186/s12967-024-05506-y.


Pivotal role of intestinal cholesterol and nuclear receptor LXR in metabolic liver steatohepatitis and hepatocarcinoma.

Piccinin E, Arconzo M, Pasculli E, Tricase A, Cultrera S, Bertrand-Michel J Cell Biosci. 2024; 14(1):69.

PMID: 38824560 PMC: 11144344. DOI: 10.1186/s13578-024-01248-y.


Establishment and validation of serum lipid-based nomogram for predicting the risk of prostate cancer.

Feng F, Zhong Y, Chen Y, Lin F, Huang J, Mai Y BMC Urol. 2023; 23(1):120.

PMID: 37452418 PMC: 10349516. DOI: 10.1186/s12894-023-01291-w.


Folate Metabolism in Hepatocellular Carcinoma. What Do We Know So Far?.

Quevedo-Ocampo J, Escobedo-Calvario A, Souza-Arroyo V, Miranda-Labra R, Bucio-Ortiz L, Gutierrez-Ruiz M Technol Cancer Res Treat. 2022; 21:15330338221144446.

PMID: 36503290 PMC: 9749048. DOI: 10.1177/15330338221144446.


References
1.
Furuhashi M, Hotamisligil G . Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008; 7(6):489-503. PMC: 2821027. DOI: 10.1038/nrd2589. View

2.
Gomez-Quiroz L, Seo D, Lee Y, Kitade M, Gaiser T, Gillen M . Loss of c-Met signaling sensitizes hepatocytes to lipotoxicity and induces cholestatic liver damage by aggravating oxidative stress. Toxicology. 2016; 361-362:39-48. PMC: 5131870. DOI: 10.1016/j.tox.2016.07.004. View

3.
Tsuchida T, Lee Y, Fujiwara N, Ybanez M, Allen B, Martins S . A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol. 2018; 69(2):385-395. PMC: 6054570. DOI: 10.1016/j.jhep.2018.03.011. View

4.
Lee C, Cheung S . STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma. Cancers (Basel). 2019; 11(11). PMC: 6895841. DOI: 10.3390/cancers11111646. View

5.
Huang D, El-Serag H, Loomba R . Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2020; 18(4):223-238. PMC: 8016738. DOI: 10.1038/s41575-020-00381-6. View